ArticleMedicine2020

Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy.

Marinel Ocasio-Rivera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.